• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Biogen (BIIB)

Common Shares
Sell: $250.00|Buy: $253.50|Change: 3.15 (-1.24%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Address

225 Binney Street
Cambridge
MA
USA
02142

Telephone

+1 781 4642442

Website

https://www.biogen.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Biogen Inc Second Quarter Earnings Conference Call for 20272027-07-29T08:30:00
Biogen Inc Second Quarter Earnings Results for 20272027-07-29T00:00:00
Biogen Inc Annual General Meeting for 20272027-06-09T09:00:00
Biogen Inc First Quarter Earnings Conference Call for 20272027-04-29T08:00:00
Biogen Inc First Quarter Earnings Results for 20272027-04-29T00:00:00
Biogen Inc Fourth Quarter Earnings Conference Call for 20262027-02-05T08:30:00
Biogen Inc Fourth Quarter Earnings Results for 20262027-02-05T00:00:00
Biogen Inc Annual Report for 20262027-02-05T00:00:00
Biogen Inc Third Quarter Earnings Conference Call for 20262026-10-30T08:30:00
Biogen Inc Third Quarter Earnings Results for 20262026-10-30T00:00:00

Previous key dates

NameKey Date
Biogen Inc Third Quarter Earnings Conference Call for 20262026-10-30T08:30:00
Biogen Inc Third Quarter Earnings Results for 20262026-10-30T00:00:00
Biogen Inc Second Quarter Earnings Conference Call for 20262026-07-29T08:30:00
Biogen Inc Second Quarter Earnings Result for 20262026-07-29T00:00:00
Biogen Inc Annual General Meeting for 20262026-06-09T09:00:00
Biogen Inc First Quarter Earnings Conference Call for 20262026-04-29T08:00:00
Biogen Inc First Quarter Earnings Result for 20262026-04-29T00:00:00
Biogen Business Update Webcast2026-03-31T08:30:00
Biogen Inc Fourth Quarter Earnings Conference Call for 20252026-02-06T08:30:00
Biogen Inc Fourth Quarter Earnings Results for 20252026-02-06T00:00:00
Biogen Inc Annual Report for 20252026-02-06T00:00:00
Biogen Inc Third Quarter Earnings Conference Call for 20252025-10-30T08:30:00
Biogen Inc Third Quarter Earnings Result for 20252025-10-30T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.